Group 1 - The core viewpoint is that the expectation of peace talks is unlikely to materialize in the short term, primarily due to the unresolved issues surrounding Iran's nuclear development, which may lead to higher costs for negotiations and increased oil price volatility [1] - The energy and chemical sectors, which initially benefited from the war, have seen a decline in trading volume and may experience a second wave of market activity as the first round of trading concludes [1] - There is a focus on mid-term investment opportunities in high-weight value sectors such as energy, public utilities, insurance, and banking, which are expected to be favorable for low-cost entry [2] Group 2 - The innovative drug sector is experiencing a significant resurgence, driven by positive market sentiment and upcoming catalysts from conferences like AACR and ASCO, indicating a potential for fundamental and emotional resonance in the sector [3] - Eli Lilly's oral GLP-1 receptor agonist, Orforglipron, has shown superior results in clinical trials compared to existing treatments, with an expected market approval in April 2026, marking a critical phase for the global oral weight-loss drug industry [3][4] - The competitive landscape for oral GLP-1 small molecules is intensifying, with several domestic companies also advancing in clinical trials, presenting substantial market opportunities for local production chains [4]